7/103 sources · 3 publishersUpdated Oct 30, 01:43 UTC
Jefferies downgrades GlaxoSmithKline to Hold and cuts price target
Jefferies lowered its rating on GlaxoSmithKline (GSK) from Buy to Hold and reduced its target price to $55.90 from $67.40. The analyst cited a shift to limited earnings momentum, launch execution risk and fewer near‑term pipeline readouts. GSK’s shares fell about 1% to 1,814 pence after the downgrade, following a 4.8% drop on the day of its Q3 2026 results.
Why it matters
Jefferies said the reduced upside diminishes the near‑term catalyst profile, which could keep the stock under pressure despite the recent earnings beat. The lower target price may influence investors’ valuation expectations.
Key facts
- 1Jefferies changed its rating on GSK to Hold from Buy. investing.com
- 2Jefferies cut its price target on GSK to $55.90 from $67.40. investing.com
- 3GSK shares fell 1% to 1,814 pence after the downgrade. asktraders.com
- 4The stock had previously dropped 4.8% on the day of the Q3 2026 results. asktraders.com
- 5Jefferies noted GSK trades at about 10 times 2027 earnings and a PEG ratio of 0.36. investing.com
- 6The analyst referenced GSK’s £40 billion revenue ambition for 2031. asktraders.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.